Covid-19 Research

Special Issue

From Molecule to Medicine: Clinical Translation and Therapeutics

A JBRES Special Issue dedicated to rigorous, outcome-oriented translational research—linking molecular discovery, biomarker validation, drug development, and clinical therapeutics to accelerate safe and effective medicines from bench to bedside.

Home › Special Issues › From Molecule to Medicine
Submit Manuscript All Special Issues
JBRES Special Issue • Pharmaceutical & Clinical Research
Special Issue Title

From Molecule to Medicine: Clinical Translation and Therapeutics

This Special Issue of the Journal of Biomedical Research & Environmental Sciences (JBRES) invites high-quality submissions that strengthen the evidence base for translational therapeutics. We welcome work that advances biomarker discovery & validation, bridges preclinical to clinical stages, and demonstrates therapeutic efficacy & real-world impact across diverse diseases and patient populations.

Biomarkers & Translation
Predictive/prognostic biomarkers, companion diagnostics, pharmacogenomics, translational models, proof-of-concept studies, early-phase biomarkers.
Therapeutics & Development
Drug discovery pipelines, novel therapeutics, clinical trial design, personalized medicine, regulatory translation, implementation science.
Submit to This Special Issue Submission Guidelines Peer Review Policy

About this Special Issue

Translational research is strongest when it connects molecular insights with clinical application and meaningful patient outcomes. This Special Issue focuses on from molecule to medicine—from target identification and biomarker validation to therapeutic development, clinical trials, and real-world evidence. We especially welcome submissions that report transparent methods, robust endpoints, and insights that can accelerate safe, effective, and equitable medicines.

Preference is given to studies with clear outcomes (efficacy, safety, PK/PD), robust analysis, and a concise “What this changes in practice” statement.

Topics of interest

Submissions may address (but are not limited to):

Drug Discovery & Target Validation Biomarker Discovery & Qualification Preclinical to Clinical Translation Pharmacogenomics & Personalized Therapeutics Novel Drug Modalities (small molecules, biologics) Early-Phase Clinical Trials & Proof-of-Concept Companion Diagnostics Development Translational Models & Simulations Regulatory Science & IND Enabling Studies Real-World Evidence in Therapeutics Implementation & Access to New Medicines AI/ML in Drug Development Pipelines

Article types accepted

  • Original Research Articles
  • Clinical Trials & Intervention Studies
  • Observational & Population Studies
  • Review Articles
  • Systematic Reviews & Meta-Analyses
  • Mini-Reviews
  • Short Communications
  • Case Studies (where appropriate)
Tip: Include (1) primary/secondary outcomes, (2) a brief methods transparency note (preregistration/data availability if applicable), and (3) a “Clinical Relevance” paragraph.

Why submit to this Special Issue?

  • Translation-forward visibility: your work is presented alongside leading translational medicine and therapeutics research.
  • Efficient editorial pathway: JBRES targets rapid peer review (7–14 days where applicable).
  • Permanent DOI: accepted articles receive DOI for strong citation continuity.
  • Open access reach: broad discoverability for clinicians, researchers, and industry teams.
  • Author support: clear guidance through review, proofing, and publication.
Ready to submit?
Submit online, or share an abstract for an editorial scope check (methods + outcomes summary preferred).
Submit Manuscript Email Abstract
Submission Portal Submission Instructions Aims & Scope Archive
Alternative submission emails: support@jelsciences.com | editor.review@scireslit.us
License (upon publication): Creative Commons CC BY 4.0
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership